Alert detail

LCD L37905: MolDX: Envisia™, Veracyte™, Idiopathic Pulmonary Fibrosis Diagnostic Test — CGS Administrators

Policy ID: LCD-L37905Specialty: PulmonologyAdded: 6/5/2026Effective: May 28, 2026lcd
High

What changed

Envisia and Veracyte IPF tests covered under Medicare LCD.

Who’s affected: Pulmonology billing teams · Effective: May 28, 2026

Affected codes

Codes81554

Primary source: View the official CMS/MAC document ↗

Get the action steps and full analysis

This change affects 1 billing code.

Subscribers get the recommended action (“what to do”), the full AI analysis, the LCD revision comparison, and related alerts across your specialty and jurisdiction.

Audit documentation

Building an audit file?

The Tripwire Audit Pack exports 12 months of Pulmonology policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.

Get the Pulmonology audit pack — $349One-time purchase · not a subscription

Not ready to subscribe?

Get the free weekly reimbursement brief for Pulmonology— the week’s changes and deadlines, delivered to your inbox. No account required.